Evaluating Pharmacokinetics and Pharmacodynamics of Jusline
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00532766 |
Recruitment Status :
Completed
First Posted : September 20, 2007
Last Update Posted : September 26, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Jusline | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Bioequivalence of Jusline Following Subcutaneous Administration in Healthy Subjects |
Study Start Date : | November 2006 |
Actual Study Completion Date : | February 2007 |
Arm | Intervention/treatment |
---|---|
Experimental: 2
Jusline Humulin
|
Drug: Jusline
Other Name: Humulin |
- To evaluate the pharmacokinetic and pharmacodynamic profile of a new human insulin (Jusline)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy
- Non-diabetic
- Age 18-35 year
- Normal body mass index (BMI 18-25 kg/m2)
Exclusion Criteria:
- Diabetics
- Overweight/obese
- Anemic, with liver, cardiac, renal or thyroid dysfunction

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00532766
Saudi Arabia | |
University Diabetes Center | |
Riyadh, Saudi Arabia, 11461 |
Principal Investigator: | Khalid A Al-Rubeaan, MD | College of Medicine, King Saud University |
ClinicalTrials.gov Identifier: | NCT00532766 |
Other Study ID Numbers: |
CMRC06-535 |
First Posted: | September 20, 2007 Key Record Dates |
Last Update Posted: | September 26, 2007 |
Last Verified: | September 2007 |
Healthy subjects |